<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913900</url>
  </required_header>
  <id_info>
    <org_study_id>H-2009-0008</org_study_id>
    <nct_id>NCT00913900</nct_id>
  </id_info>
  <brief_title>Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease</brief_title>
  <acronym>SCRIPT-CLI</acronym>
  <official_title>Stem Cell Revascularization in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral artery disease (PAD) due to leg artery blockages can result in painful leg
      muscles, skin ulcers and infection due to poor blood flow. In severe forms, the only
      treatment may be amputation. Adult stem cells injected into affected legs may cause new blood
      vessel formation and improve blood flow. The purpose of this study is to determine the
      feasibility and safety of injecting adult stem cells into the leg muscles of patients with
      severe PAD, in an attempt to improve blood flow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower extremity peripheral artery disease (PAD) is a common, debilitating and potentially
      life-threatening illness. Obstructive PAD can progress to limb-threatening ischemia with rest
      pain, ulcers, and gangrene requiring amputation unless blood flow to the ischemic limb can be
      restored. Surgical revascularization options are often limited by arteries that are too small
      to bypass. Patient co-morbidities also make surgical options risky. Percutaneous
      revascularization techniques are similarly limited by small distal artery caliber, technical
      difficulty and high restenosis rates. Amputation may be the only treatment option for
      non-healing ulcers or gangrene. Direct intramuscular injection of adult stem cells may result
      in improved lower extremity perfusion, symptomatic improvement and limb salvage in patients
      with critical limb ischemia not optimal for conventional revascularization. This study aims
      to demonstrate the safety and feasibility of this therapeutic approach.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to mobilize adequate CD34+ stem cells for minimum study treatment dose.
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or amputation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular hemodynamics and function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Arterial Occlusive Disease</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Autologous Stem cells (CD133+)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous CD133+ cells</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Autologous Stem cells (CD133+)</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory critical limb ischemia (Rutherford Score 4/5)

          -  Not optimal for surgical or catheter-based revascularization

          -  Obstructive atherosclerosis of at least 1 major artery in both limbs

          -  Ankle-Brachial Index &lt;0.6 or Absolute Ankle pressure &lt;60mmHg or toe pressure &lt;40mmHg
             or pulse volume recording that is flat or barely pulsatile

        Exclusion Criteria:

          -  Gangrene(Rutherford 6) or pre-existing major tissue loss

          -  Unstable Angina, MI, stroke, CHF (class III or IV) within 6 months of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amish N Raval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.Wisconsin School of Medicine and Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Raval AN, Schmuck EG, Tefera G, Leitzke C, Ark CV, Hei D, Centanni JM, de Silva R, Koch J, Chappell RG, Hematti P. Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial. Cytotherapy. 2014 Dec;16(12):1720-32. doi: 10.1016/j.jcyt.2014.07.011. Epub 2014 Sep 18.</citation>
    <PMID>25239491</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterial Occlusive Diseases</keyword>
  <keyword>Vascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

